GlobeNewswire: Provectus Biopharmaceuticals Inc. Contains the last 10 of 126 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T09:27:25ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853087/0/en/Provectus-Biopharmaceuticals-Announces-Exclusive-Worldwide-License-Agreement-with-University-of-Miami-for-Photodynamic-Antimicrobial-Treatment-of-Different-Eye-Infections-with-Rose.html?f=22&fvtc=4&fvtv=39759Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium2024-03-27T12:00:00Z<![CDATA[KNOXVILLE, TN, March 27, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it has entered into an agreement with the University of Miami (the “University”) for the exclusive worldwide license of the University’s intellectual property related to photodynamic antimicrobial therapy (“PDAT”) for treating bacterial, fungal, and parasitic (acanthamoeba) infections of the eye.]]>https://www.globenewswire.com/news-release/2024/03/12/2844470/0/en/Provectus-Biopharmaceuticals-Announces-Notices-of-Allowance-and-Award-for-U-S-Patents-of-Rose-Bengal-Sodium-in-Virology-Pediatric-Solid-Tumor-Cancers-and-Vaccines.html?f=22&fvtc=4&fvtv=39759Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines2024-03-12T12:00:00Z<![CDATA[KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (“USPTO”) has allowed patent application 17/212,723, titled “Novel Uses of Halogenated Xanthenes in Oncology and Virology.” The application covers the use of Provectus’s pharmaceutical-grade rose bengal sodium (“RBS”) drug substance for the treatment of infectious diseases, such as coronaviruses.]]>https://www.globenewswire.com/news-release/2024/03/07/2842200/0/en/Provectus-Biopharmaceuticals-Announces-Acceptance-of-Cancer-Immunotherapy-PV-10-Abstract-for-HNSCC-at-AACR-2024-Annual-Meeting.html?f=22&fvtc=4&fvtv=39759Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting2024-03-07T13:00:00Z<![CDATA[KNOXVILLE, TN, March 07, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research on PV-10 (rose bengal sodium) for the treatments of human papillomavirus (“HPV”)-positive and HPV-negative head and neck squamous cell carcinoma (“HNSCC”) will be presented at the upcoming annual meeting of the American Association for Cancer Research (“AACR”), to be held April 5-10, 2024 in San Diego, California.]]>https://www.globenewswire.com/news-release/2024/02/29/2837907/0/en/Provectus-Biopharmaceuticals-Announces-Acceptance-of-Pharmaceutical-Grade-Rose-Bengal-Sodium-Abstract-for-Poster-Presentation-at-2024-Society-for-Investigative-Dermatology-SID-Annu.html?f=22&fvtc=4&fvtv=39759Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting2024-02-29T13:00:00Z<![CDATA[KNOXVILLE, TN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from ongoing preclinical research on the topical administration of a formulation of Provectus’s proprietary, pharmaceutical-grade, small molecule, rose bengal sodium (“RBS”) drug substance are being presented at the annual meeting of the Society for Investigative Dermatology (“SID”), to be held May 15-18, 2024 in Dallas, Texas.]]>https://www.globenewswire.com/news-release/2024/02/15/2829892/0/en/Provectus-Biopharmaceuticals-Announces-First-Quarter-2024-Conference-Call.html?f=22&fvtc=4&fvtv=39759Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call2024-02-15T13:00:00Z<![CDATA[KNOXVILLE, TN, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will host a conference call starting at 3 p.m. EST on Thursday, February 22, 2024, to provide Company updates.]]>https://www.globenewswire.com/news-release/2024/02/14/2829032/0/en/Provectus-Biopharmaceuticals-Engages-irlabs-for-Investor-Relations-Services.html?f=22&fvtc=4&fvtv=39759Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services2024-02-14T13:00:00Z<![CDATA[KNOXVILLE, TN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it has engaged IR Labs, Inc. (“irlabs”) to develop a comprehensive investor relations and corporate communications program for the Company.]]>https://www.globenewswire.com/news-release/2023/12/18/2797781/0/en/Provectus-Biopharmaceuticals-Announces-Notice-of-Allowance-of-First-U-S-Patent-of-Rose-Bengal-Sodium-for-Use-as-Anticancer-and-Antiviral-Vaccine-Adjuvant.html?f=22&fvtc=4&fvtv=39759Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant2023-12-18T13:00:00Z<![CDATA[KNOXVILLE, TN, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed patent application 17/488,430, titled “Halogenated Xanthenes as Vaccine Adjuvants.” The allowed patent application covers the use of Provectus’s pharmaceutical-grade rose bengal sodium (RBS) drug substance as an adjuvant in anticancer, antiviral, and possibly other vaccines to potentially make them work better by enhancing T-cell response.]]>https://www.globenewswire.com/news-release/2023/11/15/2781093/0/en/Provectus-Biopharmaceuticals-Provides-Updated-Data-on-Cancer-Immunotherapy-PV-10-for-Advanced-Cutaneous-Melanoma.html?f=22&fvtc=4&fvtv=39759Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma2023-11-15T14:00:00Z<![CDATA[KNOXVILLE, TN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) in combination with standard of care immune checkpoint blockade (CB) for the treatment of advanced cutaneous melanoma (NCT02557321).]]>https://www.globenewswire.com/news-release/2023/11/13/2778972/0/en/Provectus-Biopharmaceuticals-Provides-Updated-Data-on-Cancer-Immunotherapy-PV-10-for-Metastatic-Uveal-Melanoma.html?f=22&fvtc=4&fvtv=39759Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma2023-11-13T13:00:00Z<![CDATA[KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) (NCT00986661).]]>https://www.globenewswire.com/news-release/2023/11/06/2774045/0/en/Provectus-Biopharmaceuticals-Announces-Presentation-of-Preclinical-PV-10-Vaccine-Adjuvant-Data-at-Society-for-Immunotherapy-of-Cancer-SITC-2023-Annual-Meeting.html?f=22&fvtc=4&fvtv=39759Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting2023-11-06T13:00:00Z<![CDATA[KNOXVILLE, TN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy PV-10 (rose bengal sodium) as an adjuvant in vaccines to help them work better was the subject of a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2023 annual meeting, which was held in San Diego, CA from November 1-5. This research has been led by Aru Narendran, MD, PhD and his lab team from the Cumming School of Medicine at the University of Calgary in Alberta, Canada.]]>